- Home
- ERAS vs CYRX Comparison
ERAS vs CYRX Comparison
Compare ERAS & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- CYRX
- Stock Information
- Founded
- ERAS 2018
- CYRX 1999
- Country
- ERAS United States
- CYRX United States
- Employees
- ERAS N/A
- CYRX N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- CYRX Biotechnology: Pharmaceutical Preparations
- Sector
- ERAS Health Care
- CYRX Health Care
- Exchange
- ERAS Nasdaq
- CYRX Nasdaq
- Market Cap
- ERAS 439.7M
- CYRX 438.7M
- IPO Year
- ERAS 2021
- CYRX N/A
- Fundamental
- Price
- ERAS $1.71
- CYRX $8.99
- Analyst Decision
- ERAS Buy
- CYRX Strong Buy
- Analyst Count
- ERAS 6
- CYRX 10
- Target Price
- ERAS $3.83
- CYRX $11.70
- AVG Volume (30 Days)
- ERAS 964.1K
- CYRX 578.8K
- Earning Date
- ERAS 11-11-2025
- CYRX 11-06-2025
- Dividend Yield
- ERAS N/A
- CYRX N/A
- EPS Growth
- ERAS N/A
- CYRX N/A
- EPS
- ERAS N/A
- CYRX 1.35
- Revenue
- ERAS N/A
- CYRX $237,879,000.00
- Revenue This Year
- ERAS N/A
- CYRX N/A
- Revenue Next Year
- ERAS N/A
- CYRX $9.08
- P/E Ratio
- ERAS N/A
- CYRX $6.66
- Revenue Growth
- ERAS N/A
- CYRX 24.93
- 52 Week Low
- ERAS $1.01
- CYRX $4.58
- 52 Week High
- ERAS $3.31
- CYRX $10.46
- Technical
- Relative Strength Index (RSI)
- ERAS 59.36
- CYRX 51.87
- Support Level
- ERAS $1.53
- CYRX $8.53
- Resistance Level
- ERAS $1.69
- CYRX $10.46
- Average True Range (ATR)
- ERAS 0.10
- CYRX 0.57
- MACD
- ERAS 0.01
- CYRX -0.09
- Stochastic Oscillator
- ERAS 96.20
- CYRX 36.91
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.